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Introduction
============

Hedgehog signaling is involved in embryonic development and plays an important role in the maintenance of stem cells, tissue repair and regeneration in adult organisms \[[@R1]--[@R4]\]. The erroneous activation of hedgehog signaling is tightly associated with the occurrence of basal cell carcinoma and medulloblastoma \[[@R5]\]. In addition, several other tumors are co-dependent on hedgehog signaling, examples for this type are cancers of the skin \[[@R6]--[@R7]\], brain \[[@R8]--[@R9]\], lung \[[@R10]\], pancreas \[[@R11]\], breast \[[@R12]\], prostate \[[@R13]--[@R14]\], colon \[[@R15]\], rhabdomyosarcoma \[[@R16]\], lymphoma \[[@R17]--[@R19]\], multiple myeloma \[[@R17],[@R20]\], and chronic myeloic leukemia \[[@R21]--[@R23]\]. More recently, other diseases like diabetes \[[@R24]--[@R25]\], neurodegenerative disorders \[[@R26]\], and trisomy \[[@R27]--[@R28]\], have been linked with hedgehog signaling.

Cyclopamine (**1**, see [Fig. 1](#F1){ref-type="fig"}) was the first inhibitor of the hedgehog signaling pathway to be identified. As a highly selective inhibitor of the transmembrane protein Smoothened (Smo), an integral component of hedgehog signaling, it presents an attractive target for medicinal and pharmaceutical research \[[@R29]--[@R30]\]. Unfortunately, its direct development into a drug is hampered by its low metabolic stability (decomposition at pH \< 3) \[[@R31]\] and rather moderate potency (IC~50~ \~ 5 µM).

![Structures of cyclopamine and *exo*-cyclopamine.](Beilstein_J_Org_Chem-09-2328-g002){#F1}

We previously reported the first chemical synthesis of cyclopamine (**1**) starting from dehydroepiandrosterone and utilizing the C--H-functionalization logic and a biomimetic skeleton rearrangement \[[@R32]--[@R33]\]. Furthermore, quantum mechanical calculations guided our design and synthesis of *exo*-cyclopamine (**2**, see [Fig. 1](#F1){ref-type="fig"}), a ten-fold more potent and acid-stable analog with an *exo*-methylene unit at C13--C18 \[[@R34]\]. Herein, we describe a comprehensive study of cyclopamine analogs bearing *exo*-methylene units in different positions and extent this rational to F-ring-modified structures.

Results and Discussion
======================

Our synthetic approach to the analogs described here started from previously reported azide **3** which was converted in six steps \[[@R32]\] to the protected bis-*exo*-methylene compound **4**. Carefully chosen conditions for the deprotection of the benzyl ether (DDQ, DCE/pH 7 phosphate buffer, 40 °C, 86%) and the benzenesulfonylamine (sodium naphthalenide, DME, −78 °C, 79%) allowed for the isolation of bis-*exo*-cyclopamine **6** in 18% overall yield from **3**. The hydrogenation of intermediate **4** by using Wilkinson's catalyst in benzene yielded previously described *exo*-cyclopamine **2** and its C25 epimer **5**. Deprotection with Raney-nickel (EtOH, 78 °C) and then sodium naphthalenide (DME, −78 °C, 41% over two steps) furnished 25-epi-*exo*-cyclopamine **5** in 3% overall yield from **3**.

A first set of *exo*-cyclopamine analogs with a modified F-ring was obtained starting again from azide **3** (see [Scheme 1](#C1){ref-type="fig"}). Reduction of the lactone moiety to give a tetrahydrofuran was accomplished in three steps including (1) partial reduction to the lactol (DIBAl-H, THF, −78 °C to −60 °C, 95%), (2) acetylation (Ac~2~O, pyridine, cat. DMAP, quant.) and (3) reductive removal of the so-obtained acetate (Et~3~SiH, BF~3~·Et~2~O, −78 °C to −20 °C, 79%). Removal of the benzyl ether, reduction of the azide moiety and concomitant alkylation was then all effected in one pot by using Raney-nickel in EtOH to give analog **8**, an F-ring-opened *exo*-cyclopamine derivative in 27% overall yield from **3**. Alternatively, the use of previously devised conditions for benzyl deprotection (DDQ, DCE/pH 7 phosphate buffer, 45 °C, 78%) and then sodium borohydride-mediated reduction of the azide (EtOH, 65 °C, 62%) cleanly furnished primary amine **9**, an *exo*-cyclopamine derivative with no F-ring (35% overall yield from **3**).

![Synthesis of 25-epi-*exo*-cyclopamine **5**, bis-*exo*-cyclopamine **6**, and derivatives **8** and **9**. Reaction conditions: (a) DIBAl-H, THF, −78 °C to −65 °C, 4 h, 95%; (b) Ac~2~O, pyridine, DMAP (cat.), 25 °C, 20 h, quant; (c) BF~3~·Et~2~O, Et~3~SiH, CH~2~Cl~2~, −78 °C to −20 °C, 7 h, 79%; (d) Rh(PPh~3~)~3~Cl, benzene, H~2~, 25 °C, 24 h, quant. (3:1 dr); (e) Raney-nickel (W2), EtOH, 78 °C, 5 min; (f) sodium naphthalenide, DME, −78 °C, 30 min, 41% over two steps; (g) DDQ, DCE/phosphate buffer (pH 7), 40 °C, 95 min, 86%; (h) sodium naphthalenide, DME, −78 °C, 1 h, 79%; (i) Raney-nickel (W2), EtOH, 37%; (j) DDQ, DCE/phosphate buffer (pH 7), 45 °C, 1.5 h, 78%, (k) NaBH~4~, EtOH, 65 °C, 5 d, 62%.](Beilstein_J_Org_Chem-09-2328-g004){#C1}

A second set of F-ring-modified *exo*-cyclopamine derivatives was obtained starting from previously described 12-ß-triethylsilyloxy compound **10** (see [Scheme 2](#C2){ref-type="fig"}) \[[@R32]\]. To construct the spirolactone **12**, a three-step process consisting of (1) allylation (allylcerium chloride, THF, 0 °C, 93%), (2) hydroboration/oxidation (9-BBN, THF, 70 °C; then NaBO~3~, H~2~O, 50 °C, 91%) and finally, (3) oxidative cyclization (BAIB, cat. TEMPO, CH~2~Cl~2~, 25 °C, 73%) was employed. Deprotection of the silyl ether (HF, MeCN, 25 °C, 87%) and base-induced rearrangement of the steroid skeleton via the corresponding triflate (Tf~2~O, pyridine, 0 °C→50 °C, 46%) gave C-*nor*-D-*homo*-derivative **13** which, in turn, was transformed into lactone azide **14** by using Evans' conditions (LDA, THF, −78 °C to −30 °C, 10 min; then trisylazide, THF, −78 °C, 1.5 h, 43%) \[[@R35]\]. From **14** two additional *exo*-cyclopamine derivatives became accessible. Partial reduction to the lactol (DIBAl-H, THF, −78 °C to −65 °C, 88%) and Horner--Wadsworth--Emmons reaction by using previously reported dimethyl {3-\[(4-methoxybenzyl)oxy\]-2-oxopropyl}phosphonate \[[@R32]\], (Ba(OH)~2~, THF/H~2~O, 80 °C, 50%) led to **15** which, in turn, was methylenated by employing the Peterson protocol (TMSCH~2~CeCl~2~, THF, −78 °C; then TMEDA; then HF, MeCN, 25 °C, 64%) \[[@R36]\]. Towards this end the azide moiety was reduced and monoprotection of the so-obtained amine as a sulfonamide (LiAlH~4~, THF, 0 °C→25 °C; then benzenesulfonyl chloride, Et~3~N, DMF, 0 °C, 69%) gave **17**. Deprotetion of the 4-methoxybenzyl ether (DDQ, DCE/pH 7 phosphate buffer, 25 °C, 59%) and cyclization under Mitsunobu conditions (*n*-Bu~3~P, DEAD, toluene, 0 °C→25 °C, 93%) yielded piperidine **18**. Deprotection of the benzyl ether by using previously devised conditions (DDQ, DCE/pH 7 phosphate buffer, 44 °C, 70%) and the benzenesulfonylamine (sodium naphthalenide, DME, −78 °C, 95%) gave 20-demethyl-bis-*exo*-cyclopamine **19** in 7% overall yield starting from **14**.

![Synthesis of 20-demethyl-bis-*exo*-cyclopamine **19** and F-*nor*-20,25-bis-demethyl-*exo*-cyclopamine **23**. Reaction conditions: (a) allylcerium chloride, THF, 0 °C, 30 min, 93%; (b) 9-BBN, THF, 70 °C, 6 h; then NaBO~3~, 50 °C, 12 h, 91%; (c) BAIB, TEMPO, CH~2~Cl~2~, 25 °C, 3 h, 73%; (d) HF 50 wt % in H~2~O, MeCN, 20 min, 25 °C, 87%; (e) Tf~2~O, pyridine, 0 °C→50 °C, 1.5 h; then additional Tf~2~O, 0 °C→50 °C, 2 h, 46%; (f) LDA, THF, −78 °C to −30 °C, 10 min; then trisylazide, THF, −78 °C, 1.5 h, 43%; g) DIBAl-H, THF, −78 °C to −65 °C, 2 h, 88%; (h) dimethyl (3-((4-methoxybenzyl)oxy)-2-oxopropyl)phosphonate, Ba(OH)~2~, THF/H~2~O, 80 °C, 13 h, 50%; (i) (trimethylsilyl)methylcerium chloride, THF, −78 °C, 30 min; then TMEDA, −78 °C, 15 min; then HF 50 wt % in H~2~O, MeCN, 25 °C, 10 min, 64%; (j) LiAlH~4~, THF, 0 °C→25 °C, 13 h; then benzenesulfonyl chloride, Et~3~N, DMF, 0 °C, 25 min, 69%; (k) DDQ, CH~2~Cl~2~/phosphate buffer (pH 7), 25 °C, 2 h, 59%; (l) *n*-Bu~3~P, DEAD, toluene, 0 °C→25 °C, 12 h, 93%; (m) DDQ, DCE/phosphate buffer (pH 7), 44 °C, 50 min, 70%; (n) sodium naphthalenide, DME, −78 °C, 30 min, 95%; (o) triethyl phosphonoacetate, Ba(OH)~2~, THF, 80 °C, 12 h, 55%; (p) PPh~3~, THF/H~2~O, 50 °C, 24 h; then benzenesulfonyl chloride, Et~3~N, CH~2~Cl~2~, 40 °C, 5 h, 97%; (q) DIBAl-H, THF, −78 °C to −40 °C, 3 h, 97%; (r) *n*-Bu~3~P, DEAD, toluene, 0 °C→25 °C, 24 h, 81%; (s) DDQ, DCE/phosphate buffer (pH 7), 40 °C, 30 min, 62%; (t) sodium naphthalenide, DME, −78 °C, 40 min, 74%.](Beilstein_J_Org_Chem-09-2328-g005){#C2}

Starting from azido lactone **14** (see [Scheme 2](#C2){ref-type="fig"}) a partial reduction to the lactol (DIBAl-H, THF, −78 °C to −65 °C, 88%) and the Horner--Wadsworth--Emmons reaction by using triethyl phosphonoacetate (Ba(OH)~2~, THF/H~2~O, 80 °C, 55%) led to ethyl ester **20**. Reduction of the azide moiety in **20** was carried out by using Staudinger's protocol (Ph~3~P, THF/H~2~O, 50 °C). Immediate protection of the obtained amine (benzenesulfonyl chloride, Et~3~N, CH~2~Cl~2~, 40 °C, 97% over 2 steps) gave sulfonylamide **21**. Reduction of the ester in **21** to the primary alcohol (DIBAl-H, THF, −78 °C to −40 °C, 97%) and cyclization by employing Mitsunobu conditions (*n*-Bu~3~P, DEAD, toluene, 0 °C→25 °C, 81%) yielded pyrrolidine **22**. Previously devised conditions for the deprotection (1. DDQ, DCE/pH 7 phosphate buffer, 40 °C; 2. sodium naphthalenide, DME, −78 °C, 46%) finally afforded F-*nor*-20,25-bis-demethyl-*exo*-cyclopamine **23** in 9% overall yield starting from **14**.

Next, we examined all synthesized compounds for their ability to inhibit the Gli1-dependent luciferase expression in Shh-LIGHTII cells, a clonal mouse fibroblast cell line which stably incorporates a Gli-dependent firefly luciferase reporter and a constitutive *Renilla* luciferase reporter \[[@R37]\]. The compounds were tested in a concentration range from 0.01 μM to 10 μM. While analogs **8**, **9**, and **19** showed no activity (data not shown) in this concentration range, **5**, **6**, and **23** were active with 25-epi-*exo*-cyclopamine **5** having an IC~50~ of 3.29 ± 0.31 μM, F-*nor*-20,25-bis-demethyl-*exo*-cyclopamine **23** of 6.4 ± 0.9 μM, and bis-*exo*-cyclopamine **6** being the most active with an IC~50~ of 0.20 ± 0.01 μM (see [Fig. 2](#F2){ref-type="fig"}).

![IC~50~ values of Shh inhibition by compounds **5**, **6** and **23** in a Gli1-reporter gene assay. Data were obtained from three independent experiments and represent the mean ± standard deviation.](Beilstein_J_Org_Chem-09-2328-g003){#F2}

Given the negative test results of compounds **8** and **9** it becomes evident that the F-ring is necessary for bioactivity. The piperidine moiety provides a rather rigidly placed nitrogen atom. Nevertheless, a pyrrolidine as in compound **23** still provides the correct orientation of the nitrogen atom. Despite compounds **8** and **9** being inactive in the assay, both derivatives induced cytotoxicity in the concentration range tested. Very subtle changes of the conformation of the piperidine ring significantly change bioactivity: While 25-epi-*exo*-cyclopamine **5** shows reduced activity in comparison to *exo*-cyclopamine **2**, bis-*exo*-cyclopamine **6** is the most active compound tested in this study. Furthermore, the methyl group at C-20 seems to have a pronounced effect on the bioactivity, with 20-demethyl-bis-*exo*-cyclopamine **19** being completely inactive in the tested concentration range.

Finally, we studied the stability of all newly synthesized compounds towards acidic conditions. Therefore, they were exposed to a pH of approximately 1 (MeOH, 1 M HCl) for 24 h. After evaporation of all volatiles, ^1^H NMR spectra were acquired and compared to the initially obtained spectra of the pure compounds. While compounds **5**, **6**, **8**, and **9** remained unchanged, compounds **19** and **23** showed decomposition. This experiment emphasizes the importance of the C-21 methyl group for the stability of *exo*-cyclopamine derivatives. All synthesized compounds, the number of steps required, and the respective overall yield starting from **3** or **14**, as well as their biological activity and stability under acidic conditions are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Synthesized *exo*-cyclopamine derivatives, number of steps, yields, results of their biological testing, and stability towards acid.

  ------------------------------------------------------ -------------------------------------- --------------- ---------------------- ---------------------------------------
  Compound                                               Number of steps from **3** or **14**   Overall yield   Potency in Gli-assay   Stability towards acid (pH \~1, 24 h)

                                                                                                                                       

  ![](Beilstein_J_Org_Chem-09-2328-i001.jpg)\            9 steps from **3**                     3%              3.29 ± 0.31 µM         stable
  **5**: 25-epi-*exo*-cyclopamine                                                                                                      

  ![](Beilstein_J_Org_Chem-09-2328-i002.jpg)\            8 steps from **3**                     18%             0.2 ± 0.01 µM          stable
  **6**: bis-*exo*-cyclopamine                                                                                                         

  ![](Beilstein_J_Org_Chem-09-2328-i003.jpg)\            4 steps from **3**                     27%             \> 10 µM               stable
  **8**                                                                                                                                

  ![](Beilstein_J_Org_Chem-09-2328-i004.jpg)\            5 steps from **3**                     35%             \> 10 µM               stable
  **9**                                                                                                                                

  ![](Beilstein_J_Org_Chem-09-2328-i005.jpg)\            8 steps from **14**                    7%              \> 10 µM               decomp.
  **19**: 20-demethyl-bis-*exo*-cyclopamine                                                                                            

  ![](Beilstein_J_Org_Chem-09-2328-i006.jpg)\            7 steps from **14**                    9%              6.40 ± 0.90 µM         decomp.
  **23**: F-*nor*-20,25-bis-demethyl-*exo*-cyclopamine                                                                                 

  Previously synthesized and biologically evaluated:                                                                                   

  ![](Beilstein_J_Org_Chem-09-2328-i007.jpg)\            9 steps from **3**                     7%              0.5 µM \[[@R34]\]      stable
  **2**: *exo*-cyclopamine                                                                                                             

  ![](Beilstein_J_Org_Chem-09-2328-i008.jpg)\            10 steps from **3**                    5%              5 µM \[[@R34]\]        decomp.
  **1**: cyclopamine                                                                                                                   
  ------------------------------------------------------ -------------------------------------- --------------- ---------------------- ---------------------------------------

Conclusion
==========

In conclusion, we succeeded in identifying the new cyclopamine derivative bis-*exo*-cyclopamine **6** which surpasses the biological potency of the parent compound by the 25-fold and is stable at pH 1. Further insights were gained into the structure--activity relationship of F-ring-modified analogs of cyclopamine and the necessity of the C-21 methyl group for bioactivity and acid stability was revealed. Our designed analogs of cyclopamine are accessible in noticeably shorter and higher yielding synthetic routes than the parent compound, a fact that will further contribute to their usefulness in biological and medicinal studies.

Supporting Information
======================

###### 

Experimental details and analytical data of all synthesized compounds are provided.
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